Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

Email Nudges Spur Patients With a History of Acute MI to Get Flu Shots

News Conference News AHA 2024

Email Nudges Spur Patients With a History of Acute MI to Get Flu Shots

November 17, 2024

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

News Conference News AHA 2022

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

Michael O'Riordan

November 06, 2022

RAPID CABG: No Penalty to Early Surgery for ACS After Stopping Ticagrelor

News Conference News AHA 2021

RAPID CABG: No Penalty to Early Surgery for ACS After Stopping Ticagrelor

Yael L. Maxwell

November 13, 2021

When PCI Decisions Ignore FFR Results, Patients Pay a Price

News Conference News AHA 2020

When PCI Decisions Ignore FFR Results, Patients Pay a Price

November 14, 2020

Complete Revascularization Benefits May Be Due to Stenting Vulnerable Plaques

News Conference News AHA 2019

Complete Revascularization Benefits May Be Due to Stenting Vulnerable Plaques

November 21, 2019

Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT

News Conference News AHA 2019

Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT

Yael L. Maxwell

November 17, 2019

RE-DUAL PCI Findings Consistent Across Key Subgroups

News Conference News AHA 2017

RE-DUAL PCI Findings Consistent Across Key Subgroups

November 16, 2017

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

News Conference News AHA 2017

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Michael O'Riordan

November 15, 2017

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

News Conference News AHA 2017

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

Yael L. Maxwell

November 14, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.